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Abstract
Aim: To systematically review human metabolomic studies investigating metabolic 
responses in septic neonates.
Methods: A systematic literature search was performed in the databases MEDLINE, 
EMBASE and Cochrane library up to the 1st of January 2021. We included studies 
that assessed neonatal sepsis and the following outcomes; (1) change in the metabo-
lism compared to healthy neonates and/or (2) metabolomics compared to traditional 
diagnostic tools of neonatal sepsis. The screened abstracts were independently con-
sidered for eligibility by two researchers. PROSPERO ID: CRD42020164454.
Results: The search identified in total 762 articles. Fifteen articles were assessed for 
eligibility. Four studies were included, with totally 78 neonates. The studies used dif-
ferent diagnostic criteria and had between 1 and 16 sepsis cases. All studies with 
bacterial sepsis found alterations in the glucose and lactate metabolism, reflecting 
possible redistribution of glucose consumption from mitochondrial oxidative phos-
phorylation to the lactate and pentose phosphate pathway. We also found signs of 
increased oxidative stress and fatty acid oxidation in sepsis cases.
Conclusion: We found signs of metabolomic signatures in neonatal sepsis. This may 
lead to better understanding of sepsis pathophysiology and detection of new candi-
date biomarkers. Results should be validated in large- scale multicentre studies.
K E Y W O R D S
newborn infant, metabolomics, neonatal sepsis
Key notes
• This is a systematic review of human metabolomic studies investigating metabolic responses 
in neonates with sepsis compared with healthy control infants.
• Publications up to January 2021 were reviewed and four case- control studies with 78 neo-
nates were included.
• Sepsis cases showed alterations in the glucose and lactate metabolism, and signs of increased 
oxidative stress and fatty acid oxidation. Larger studies are needed to validate the metabo-
lomic signatures in neonatal sepsis.
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1  |  INTRODUC TION
Neonatal sepsis is a serious and potentially fatal condition. Globally, 
around 2% of all live- born infants develop sepsis within 28 days of 
life, with an estimated sepsis- attributable case mortality of 11%– 
19%.1 In high- income countries, neonatal sepsis is also a serious 
threat, in particular to preterm infants.2 However, unlike in adults3 
there is no undisputable uniform definition for neonatal sepsis.4 
This hampers comparison of studies and limit our pathophysi-
ological understanding. Isolation of a pathogen in a microbiological 
culture of blood or cerebrospinal fluid is by many considered the 
diagnostic ‘gold standard’. Adjunctive, but imperfect biomarkers 
supporting a sepsis diagnosis include C- reactive protein (CRP), pro-
calcitonin (PCT) and haematological indices. There has also been 
extensive research in other biomarkers, but currently there is no 
single biomarker or panel of markers to specifically diagnose neo-
natal sepsis.5– 10
Immunometabolism is an emerging field recognising the com-
plex interactions between the metabolism and the immune system 
both in infections and other diseases. Recent studies suggest that 
sepsis simultaneously induces both hyper- and hypo- inflammatory 
responses.11 Moreover, some studies report a correlation between 
early deaths and an acute hyper- inflammatory phase, whereas late 
deaths are associated with a prolonged immunosuppression and re-
current infection.12,13 Sepsis causes a dysregulation of the metabo-
lome by inducing hypoxia, oxidative stress and high energy demand. 
Metabolomics can characterise the normal state of neonates and the 
metabolic state during sepsis, also in the hopes of identifying novel 
biomarkers/biomarker panels.14,15
We have performed a systematic review of publications evaluat-
ing the metabolomic response in neonates with sepsis. Our aim was 
to characterise metabolome patterns during infection, and how this 
can be used to better understand sepsis pathophysiology and possi-
bly increase diagnostic accuracy of neonatal sepsis.
2  |  METHODS
This systematic review is registered in the international prospective 
register of systematic reviews; PROSPERO ID: CRD42020164454.
2.1  |  Search strategy
We developed our search strategy in consultation with a librar-
ian. The search for articles was performed in the high- quality 
databases MEDLINE, EMBASE and the Cochrane library up to 
1 January 2021. The first search was conducted by combining 
the MeSH terms ‘Neonatal sepsis’ and ‘Metabolomics’, with ad-
ditional appropriate free text search words (Figure S1). All titles 
and abstracts of all articles citing metabolic testing in diagnosing 
neonatal sepsis identified through Google Scholar and/or Scopus/
Web of Science search engines were also reviewed. We examined 
reference lists of included studies and relevant reviews to identify 
additional eligible studies. Identified studies were collated and du-
plicates/triplicates were manually removed. We did not perform 
searches in the ‘grey literature’, that is unpublished studies, non- 
peer reviewed studies and abstracts and studies not indexed in 
high- quality databases.
2.2  |  Study selection and eligibility criteria
Inclusion criteria were term born neonates (age 0– 28 days) or pre-
term neonates up to 44 weeks postmenstrual age with a systemic 
infection and evaluated with metabolomic profiling using one of the 
following techniques: nuclear magnetic resonance spectrometry 
(1H- NMR), gas chromatography mass spectrometry or liquid chro-
matography tandem mass spectrometry. In the registered research 
protocol, we intended to compare metabolomic response between 
infected neonates and healthy controls, and also to compare me-
tabolomic response with traditional diagnostic tools.
All clinical trials (randomised and non- randomised), observa-
tional studies (case- control studies, retrospective cohort studies, 
prospective cohort studies, cross- sectional studies, before- after 
studies, case- series), systematic review or meta- analysis meeting 
the inclusion criteria were considered. Descriptive or narrative re-
views were not included. Full- text was read for studies eligible for 
inclusion to verify its suitability for the study.
2.3  |  Screening, data extraction and management
The screened titles and abstracts were independently considered 
for eligibility by two researchers (A.U.B. and H.N.G.) according to 
predetermined inclusion and exclusion criteria, while a third author 
(C.K.) had the decisive vote. We extracted the following information 
from included studies: study name/article, authors, year of publica-
tion, journal and full reference details, country, study design, partici-
pants, setting, investigations including metabolomics and traditional 
diagnostic tools, main results, risk of bias and statistical methods.
2.4  |  Assessment of methodological quality
The Newcastle- Ottawa Scale (NOS) was viewed appropriate to 
assess quality of the included studies. The NOS for case- control 
studies uses a ‘star system’ to judge articles on three broad per-
spectives: the selection of the study groups (maximum four stars), 
the comparability of the groups (maximum two stars) and the ex-
posure (maximum three stars); highest quality score being nine 
stars.16 Two authors (A.U.B and H.N.G) undertook this assessment 
independently and compared the findings. Disagreements were 
discussed with C.K.
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3  |  RESULTS
3.1  |  Overview of included studies
The systematic search in this review (Figure 1) resulted in the inclu-
sion of four peer- reviewed publications,17– 20 summarised in Table 1. 
The results were not possible to meta- analyse, therefore a narrative 
(descriptive) synthesis was conducted. Seventy- eight neonates were 
included in this systematic review; 33 with confirmed or possible 
infection and 45 healthy controls.17– 20
Three publications reported only data from neonates.18– 20 
Mickiewicz et al.17 included seven neonates with sepsis, but also 
infants and older children with sepsis. In this publication, neonates 
and infants were analysed together and the authors found, by using 
partial least squares discriminant analysis that the 1H- NMR metabo-
lomic profile could discriminate between septic and healthy control 
patients. However, data on specific metabolites were only reported 
for the infant group. We decided to include the ‘infant group’ (age 
1 month up to 1 year) in our qualitative analysis, because neonates 
in this study shared similar characteristics to infants in their metab-
olomic profile during sepsis. This was supported by the main study 
finding, reporting specific differences in metabolomic profile during 
sepsis mainly between school age children and those younger. The 
overall findings among children, including neonates, in this study 
was very clear separation between sepsis and healthy controls. 
Different metabolomic investigational tools were applied across all 
four studies (Table 1). Sarafidis et al.20 used a combination of tar-
geted and untargeted metabolomics (Figure 2) for the purpose of 
internally validating the metabolomic results. This was not done in 
the other included studies.
3.2  |  Quality assessment
All four included case- control studies were small. The number of 
neonates with sepsis evaluated with metabolomics varied from 
one to 16 and the number of controls varied from 13 to 16 for 
each study. Methodological quality assessment evaluated using 
the Newcastle- Ottawa scale is presented in Table 2. We consid-
ered gestational age (main confounder), postnatal age and the 
Apgar scores (proxy for perinatal asphyxia) and mode of feeding 
as the most important potential confounding factors when as-
sessing the comparability between cases and controls. All studies 
used non- infected infants recruited in the hospital as the healthy 
controls. We rewarded with one star if the controls were col-
lected from a well- described healthy population from a hospital 
setting.
3.3  |  The metabolomic profiling in the four 
included studies
All four studies showed alterations in glucose metabolism, and three 
studies showed alterations in lactate and maltose metabolism, when 
comparing sepsis cases with healthy controls (Table 1). Overall, 
we did not find any other distinct metabolomic patterns reported 
F I G U R E  1  Prisma flow diagram of 
selected articles
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across all four studies (Table 3). However, clearly some of the me-
tabolites that were increased or decreased during sepsis in all stud-
ies were connected to the same metabolomic pathways, such as the 
mitochondrial oxidative phosphorylation, the pentose phosphate 
pathway and the glycolysis or involved in oxidative stress and fatty 
acid oxidation.17– 21 None of the four studies evaluated the diagnos-
tic value of metabolomics compared to traditional diagnostic tools 
like CRP, PCT or cytokine responses.









• Septic shock, neonates (n = 5)
• SIRS/ICU, neonates (n = 2)
• Septic shock, infants (n = 21)
• SIRS/ICU, infants (n = 13)
• Healthy control infants (n = 13)
Samples were collected within 
24 h of admission to the 
PICU, or within 24 h of 
diagnosis for septic shock 
patients
• Increased: 2- hydroxybutyrate, 
2- hydroxy- isovalerate, 
2- oxoisocaproate, creatinine, 
glucose and lactate
• Decreased: 2- Aminobutyrate, 





• Fungal sepsis (n = 1)
• Healthy control (n = 13)
Urine samples were collected at 
36 h, day 7- 14- 21- 28
• Increased: D- glucose, L- 
threonine, maltose, N- glycine and 
D- serine
• Decreased: Citric acid, 









• Sepsis, neonates (n = 9)
• Healthy controls (n = 16)
Sepsis cases were both EOS 
(n = 5) and LOS (n = 4). 
Samples collected at birth 
and at regular intervals 
during the first month of life
• Increased GC- MS: Glucose, 
lactate and maltose
• Decreased GC- MS: Ribitol, 
ribonic acid, pseudo uridine, 
2,3,4- trihydroxybutyric 
acid, 2- ketogluconic acid, 
3,4- dihydroxybutanoic acid and 
3,4,5- trihydroxypentanoic acid
• Increased 1H- NMR: Acetate, 
acetone, glycine, lactate and 
glucose










• Confirmed LOS, neonates 
(n = 9)
• Possible sepsis, neonates (n = 7)
• Healthy control neonates 
(n = 16)
All sepsis cases (n = 16) were 
serially evaluated on day 
0, day 3 and day 10, thus 
covering both the acute 
phase and the recovery 
phase of sepsis
Samples from healthy controls 
were collected at the 
same time intervals after 
enrolment in the study
• Increased (1H- NMR) day 
0: Glucose, maltose, biotin, 
methylamine, inosine, 
methylguanine, creatine, 
myoinositol and quinolinic acid
• Decreased (1H- NMR) day 0: 
None reported.
• Increased (LC- MS/MS) day 0: 
Valine, phenylalanine, taurine, 
aminobutyric acid, isoleucine, 
glutamic acid, hypotaurine, 
pyruvic acid, lactic acid, glucose 
and insosine
• Decreased (LC- MS/MS) day 
0: Trimethylamine- N- oxide, 
fumaric acid, hippuric acid, 
nicotinamide, riboflavin and 
thiamine
Underlined metabolites significantly 
increased/decreased also on 
day 3, but the overall trend for 
1H- NMR and LC- MS/MS was 
that metabolic alterations in 
sepsis vs. controls were less 
different on day 3 and 10
Abbreviations: 1H NMR, proton nuclear magnetic resonance; EOS, early- onset sepsis; GC- MS, gas chromatography mass spectrometry; ICU, intensive 
care unit; LC- MS/MS, liquid chromatography tandem mass spectrometry; LOS, late- onset sepsis; SIRS, systemic inflammatory response syndrome.
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4  |  DISCUSSION
4.1  |  Key findings
Metabolomic studies allow an exact evaluation of individual meta-
bolic responses to pathophysiological stimuli, potentially useful for 
early diagnosis and management of many neonatal conditions.22 
Characterising the ontogeny of immunometabolism has recently 
been put forward as promising opportunity to prevent, diagnose and 
treat neonatal sepsis.21 In our systematic review, we identified four 
case- control studies with a total of 78 neonates characterising the 
metabolic responses in sepsis. The most salient findings were altera-
tions in glucose, lactate, 2- hydroxybutyrate and acetate metabolism 
during neonatal sepsis. Moreover, the different studies detected al-
terations in an array of metabolites that could be connected to simi-
lar metabolomic pathways. A large study assessing analytes (MS/
MS) in dried blood spots (DBS) in a newborn screening programme 
and linking these data to neonatal sepsis cases was not included as 
timing of onset of sepsis was not documented, and sepsis may have 
occurred prior to or weeks after the DBS was obtained.23
Neonates with sepsis often display disturbances in glucose me-
tabolism, both hypo- and hyperglycaemia, the latter observed in 
all studies in our review.17– 20 In particular, hyperglycaemia may be 
an important early sign of late onset sepsis in preterm infants,17,20 
reflecting both the redistribution of glucose consumption from mi-
tochondrial oxidative phosphorylation to the lactate and pentose 
phosphate pathway, and due to upregulated glycolysis in hyperin-
flammatory cells.18 Repeated blood glucose measurements for sep-
sis evaluation are, however, not feasible due to disadvantages of 
discomfort and stress for the neonate. Moreover, the association 
between a single finding of hyperglycaemia or glucosuria is too weak 
to be of diagnostic value.24 Still, our findings support the concept 
that level of glucosuria or hyperglycaemia are relevant components 
in a future (urine or blood) panel of metabolites suggestive of sep-
sis. Continuous glucose monitoring, with algorithms detecting, for 
example mean amplitude of glycaemic excursions, may in the future 
also become adjunctive tools for improved sepsis detection.25,26
In adults, a serum lactate level greater than 2 mmol/L after ade-
quate fluid resuscitation is used to identify septic shock.3,27 In children 
and neonates, lactate is neither sensitive nor specific for diagnosing 
sepsis, but mainly used to determine sepsis severity and as an indicator 
of organ dysfunction in patients with septic shock. Additionally, serial 
measurements may be useful in monitoring treatment, but lactate con-
centrations often do not increase until late in the sepsis continuum.28 
In our systematic review, lactate was increased in the sepsis group in 
three studies,17,18,20 but not in the single fungal sepsis case, described 
by Dessì et al.19 Our finding is in line with reports showing that aerobic 
glycolysis sustains the energy requirements for the activated immune 
cells.29,30 Recently, this process has also been shown to alter the me-
tabolism in a way that promotes changes in the immune cell's pheno-
type.31– 35 Even though a single lactate value is of limited prognostic 
value, greater lactate production than clearance (‘lactate kinetics’) may 
be significant despite an initial normal value.36 Overall, our findings 
support that measures of lactate metabolism should be incorporated 
in metabolic panels for sepsis. Indeed, the neonatal sepsis criteria sug-
gested by a working group in the European Medicine Agency,37 and 
later also evaluated in the study on late- onset sepsis,38 includes meta-
bolic alterations in glucose and lactate values. However, the sensitivity 
for sepsis when only using the suggested cut- off values is low.38
We observed in two studies17,20 elevated levels of 
2- oxoisocaproate, creatine, creatinine and phenylalanine; metab-
olites associated with decreased energy supply and organ failure 
during the hypo- inflammatory phase of sepsis.39– 41 There is a likeli-
hood that the two studies illustrate the same metabolomic process, 
but have identified different metabolites. We also observed increased 
levels of the organic acid 2- hydroxybutyrate17 and alterations in 
threonine metabolism.17,19 These metabolites are parts of hepatic 
metabolomic pathways associated with increased lipid oxidation and 
oxidative stress. The metabolite 2- hydroxybutyrate is also an early 
marker for insulin resistance,19,42 which often occurs during sepsis. 
Alterations in acetate levels may reflect increased fatty acid oxida-
tion.43 Through beta- oxidation, fatty acid chains are broken down 
to acetate molecules, which combined with CoA, form acetyl- CoA 
and enters the Krebs- cycle as energy substrates. Lipolysis is known 
to provide fuel for endotoxin- tolerant hypo- inflammatory immune 
cells.43 The ‘acetate switch’ hypothesis may explain diverging results 
regarding increased18 or decreased17 acetate levels during phases of 
sepsis.44 Finally, increased levels of branched- chain 2- oxo acids (eg 
2- oxoisocaproate) as observed by Mickiewicz et al.17 have been as-
sociated with dysmyelinating changes in the central nervous system 
after prolonged exposure.45
4.2  |  Strengths and limitations
The primary strength of this study is our rigorous and sensitive 
search strategy based on a previously registered search protocol. 
Additionally, characterising the metabolic responses in neonatal 
sepsis is of great clinical and scientific interest in our urge to deline-
ate pathophysiology and harmonise diagnostic criteria. The dynamic 
metabolic process during sepsis and the ambiguous clinical presen-
tation of neonatal sepsis, makes it challenging to standardise key 
variables, but three studies in our systematic review provided ad-
equate information about the diagnostic criteria for culture proven 
and culture negative neonatal sepsis.17,19,20 All four studies used bio-
logical material (urine or blood/serum) that is well- established and 
often preferred for metabolomic studies.46 Urine sampling is less 
invasive and thus an advantage given reliable and reproducible ana-
lytical results. However, urine also contains numerous metabolites 
originating from metabolised nutrients and drugs, while metabo-
lites in blood derives from metabolism of endogenous substances.47 
Thus, sampling both body fluids would have provided complemen-
tary data. Sampling of saliva is also simple and non- invasive, and may 
in neonates become a promising matrix in future studies.48
This systematic review also has several limitations. First and 
most important, only four relatively small case- control studies were 
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included and there was a large heterogeneity in study designs, out-
comes, techniques and body fluid used for metabolomic profiling 
and methodological quality. Due to the limited sample size, any sub-
group analysis based on causative pathogens was not possible. In one 
study, neonates and infants were analysed as one common group.17 
Even though this study reported similar metabolomic profiles in the 
sepsis cases below school age, a distinction between neonates and 
infants would have allowed an even more detailed assessment of the 
neonatal response. Observational studies are prone to biases and 
confounding, and in these small studies few attempts were made 
to adjust for confounding. Evidence from observational studies is 
usually considered to be of low quality. Second, the studies did not 
thoroughly record the time of day when sample were collected, and 
circadian variations may influence the metabolomic results. Third, 
the neonate's nutritional status was often not reported but should 
be carefully considered as, for example formula feeding greatly im-
pacts plasma concentrations of threonine.19,49 Only one study pro-
vided information about medications other than antibiotics.19 There 
was also little information about the quality checks for the sampling 
material and stability of metabolites over time.50 All this limit the 
quality of evidence regarding our report on significant alterations in 
metabolomic profiles during neonatal sepsis. None of the included 
publications evaluated the diagnostic value of metabolomics com-
pared with traditional diagnostic tools.
4.3  |  Implications for future research
Precision medicine led by the fields of the omics is reported to be 
the future of medicine, but there are still significant challenges to 
F I G U R E  2  (A) Untargeted metabolomics with gas or liquid chromatography (GC/LC- MS); often considered as a ‘Hypothesis- generating 
process’. Global analysis and relative quantification of a broad range of different types of metabolites including low- abundant metabolites 
and for the detection of lipid and volatile compounds. (B) Targeted metabolomics with 1H- nuclear magnetic resonance (NMR) spectroscopy; 
often considered as a ‘Hypothesis- driven process’. Absolute quantification of predetermined metabolites using commercially available 










Selection Case definition — 
Representativeness — — 
Selection of controls
Definition of controls — — 
Comparability Cases and controlsa  — — 
Exposure Ascertainment of 
exposure
— — — — 
Same method cases 
& controls
Non- Response rate — 
Total score 6 5 3 7
aFor each assessment domain, one star is maximum score, except Comparability where 2 stars is 
maximum score.
TA B L E  2  The Newcastle- Ottawa Scale 
(NOS) for included studies
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TA B L E  3  Trend of significant metabolites in the included studies
Mickiewicz 2013 Dessì 2014 Fanos 2014 Sarafidis 2017
Sepsisa  vs. Healthy (infants) Sepsis (fungal) vs Healthy Sepsisa  vs Healthy





2- ketogluconic acid ↓
2- oxoisocaproate ↑
2,3,4- trihydroxybutyric acid ↓
3,4- dihydroxybutanoic acid ↓









d- glucose ↑ ↑
d- serine ↑
Fumaric acid ↓
G- aminobutyric acid ↑
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overcome. Untargeted metabolomics (Figure 2A) is useful for a 
hypothesis- free screening in order to discover novel compositions 
of metabolites in neonatal sepsis. However, by using untargeted 
metabolomics we cannot be certain of the metabolomic pathways 
activated during neonatal sepsis.51– 53 In contrast, targeted metabo-
lomics (Figure 2B) can quantify identified metabolites and combined 
with bioinformatic analyses, activated metabolomic pathways dur-
ing sepsis can be predicted.54,55 Only a limited number of studies 
were identified in this systematic review. Translation of the hitherto 
identified metabolite biomarker panels for bedside diagnosis of 
neonatal sepsis thus remains unknown. MS/MS- based technolo-
gies are currently widely used in newborn screening of inborn er-
rors of metabolism. The advantages of this technique using very 
small blood volumes extracted from DBS may pave the way to ef-
ficient metabolite- based biomarker diagnostic tests for neonatal 
sepsis.56,57 The combined use of metabolomics with other omics 
techniques may also further enhance sensitivity and specificity for 
neonatal sepsis,11,58 but it also requires powerful computer technol-
ogy to interpret and present data in a meaningful way for clinicians.
5  |  CONCLUSION
Alterations in glucose and lactate metabolism, and signs of in-
creased oxidative stress and increased fatty acid oxidation were the 
most prominent findings. Metabolomic profiling of small volume 
samples of different body fluids combined with state- of- the- art 
bioinformatics holds promise to become powerful tools to evaluate 
and diagnose neonatal sepsis and may in the future lead to identifi-
cation of potentially new treatment strategies. Candidate metabo-
lomic biomarkers for neonatal sepsis, identified in this systematic 
review, need to be validated in large- scale multicentre studies.
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